Subscribe via E-Mail

Get all of our news delivered fresh to your inbox every morning! Just tell us your name and where to send it using the form below.

PS – We hate spam too. We don’t sell or share our list with anyone, and we never send commercial email.

* = required field

Researchers testing experimental vaccine for the Chikungunya virus

The Aedes aegypti mosquito spreads both dengue and Chikungunya virus.  Note the white stripes on its legs. (Creative Commons)

The Aedes aegypti mosquito spreads both dengue and Chikungunya virus. Note the white stripes on its legs. (Creative Commons)

 

August 15th, 2014 (VOA & InsideCostaRica.com) Researchers are testing an experimental vaccine for the Chikungunya virus.

The virus is transmitted through infected female mosquitoes that bite during the day.  The mosquitos also transmit other viral diseases including Dengue fever.

In fact, the symptoms of chikungunya – including fever, rash, headache and severe joint pain – are often mistaken for dengue, another tropical illness that causes severe aches and pains and a high fever.

Working to develop a vaccine against chikungunya – which the WHO says has reached epidemic proportions – researchers used a virus-like particle, rather than the killed or weakened virus used in traditional vaccines. The experimental drug contained outer surface proteins taken from a West African strain of chikungunya, without the genetic material that causes infection. It stimulated a robust antibody response in the majority of the 25 healthy, young American volunteers in the initial trial. The candidate vaccine was reportedly well-tolerated.  Antibody  response was seen even at the lowest doses.

More clinical trials and regulatory approval are needed before the vaccine becomes available.

In July, a French tourist became the first person to contract chikungunya in Costa Rica.  There have been several additional cases since.

An article on human trials of the experimental chikungunya vaccine is published in the journal The Lancet. 

costa rica news

ATTENTION: If you are seeing this message,


Advertisement


Get our news delivered fresh to your inbox every morning.

Click here to subscribe to our email list. We hate spam too and never send commercial email.

Like us on Facebook and receive our news in your timeline